Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a more rapid decrease in mycobacterial load, moxifloxacin containing regimens did not shorten TB treatment to 4 months as predicted.
For more information on the REMoxTB trial results, see here for the TB Alliance press release.
Publication in New England Journal of Medicine